SG156689A1 - Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate - Google Patents

Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate

Info

Publication number
SG156689A1
SG156689A1 SG200907192-9A SG2009071929A SG156689A1 SG 156689 A1 SG156689 A1 SG 156689A1 SG 2009071929 A SG2009071929 A SG 2009071929A SG 156689 A1 SG156689 A1 SG 156689A1
Authority
SG
Singapore
Prior art keywords
preparation
novel process
isoxazoline derivative
intermediate used
isoxazoline
Prior art date
Application number
SG200907192-9A
Other languages
English (en)
Inventor
Hyun Ik Shin
Hyeong Wook Choi
Tae Ho Heo
Kyu Woong Lee
Jae Hoon Lee
Ki Sook Park
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of SG156689A1 publication Critical patent/SG156689A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG200907192-9A 2005-02-26 2006-02-21 Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate SG156689A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050016203 2005-02-26

Publications (1)

Publication Number Publication Date
SG156689A1 true SG156689A1 (en) 2009-11-26

Family

ID=36927605

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907192-9A SG156689A1 (en) 2005-02-26 2006-02-21 Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate

Country Status (29)

Country Link
US (1) US8044080B2 (zh)
EP (1) EP1851214B1 (zh)
JP (1) JP4961357B2 (zh)
KR (1) KR100774999B1 (zh)
CN (1) CN101128459B (zh)
AP (1) AP2374A (zh)
AR (1) AR055314A1 (zh)
AU (1) AU2006217293B2 (zh)
BR (1) BRPI0607330B1 (zh)
CA (1) CA2598347C (zh)
DK (1) DK1851214T3 (zh)
EA (1) EA013005B1 (zh)
ES (1) ES2394480T3 (zh)
HK (1) HK1111146A1 (zh)
IL (1) IL185226A0 (zh)
MA (1) MA29311B1 (zh)
MX (1) MX2007010338A (zh)
MY (1) MY149181A (zh)
NO (1) NO341347B1 (zh)
NZ (1) NZ560805A (zh)
PE (1) PE20061076A1 (zh)
PL (1) PL1851214T3 (zh)
PT (1) PT1851214E (zh)
SG (1) SG156689A1 (zh)
SI (1) SI1851214T1 (zh)
TW (1) TWI377205B (zh)
UA (1) UA94395C2 (zh)
WO (1) WO2006090997A1 (zh)
ZA (1) ZA200707202B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101299720B1 (ko) * 2006-08-16 2013-08-28 주식회사 엘지생명과학 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법
KR20090099886A (ko) * 2008-03-18 2009-09-23 주식회사 엘지생명과학 캐스파제 저해제의 프로드럭
TW201012816A (en) * 2008-07-11 2010-04-01 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
TW201011014A (en) * 2008-07-11 2010-03-16 Gilead Sciences Inc Method of treatment and pharmaceutical compositions
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9510598B2 (en) * 2012-09-28 2016-12-06 Bayer Cropscience Ag Nitrogen-containing heterocyclic compounds for plant disease control
JP2017095353A (ja) * 2014-03-27 2017-06-01 日本曹達株式会社 イソオキサゾリン−５−カルボキサミド化合物および有害生物防除剤
CA3050832A1 (en) * 2017-01-23 2018-07-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compounds as a capase inhibitor
WO2020213970A1 (ko) * 2019-04-19 2020-10-22 주식회사 엘지화학 캐스파제 저해제의 프로드럭
KR102442103B1 (ko) * 2019-04-30 2022-09-08 주식회사 엘지화학 캐스파제 저해제의 프로드럭
JP7301448B2 (ja) * 2019-05-31 2023-07-03 エルジー・ケム・リミテッド カスパーゼ阻害剤プロドラッグを含有する注射用組成物及びその調製方法
KR102366215B1 (ko) * 2019-05-31 2022-02-22 주식회사 엘지화학 캐스파제 저해제 프로드럭의 주사용 조성물
WO2022030987A1 (ko) * 2020-08-05 2022-02-10 주식회사 엘지화학 캐스파제 저해제의 골관절염 완화 또는 치료에서의 용도
EP4248950A4 (en) 2020-11-30 2024-04-10 LG Chem, Ltd. INJECTABLE COMPOSITION CONTAINING CASPAS INHIBITOR AND MANUFACTURING METHOD THEREFOR
KR102670554B1 (ko) * 2022-01-04 2024-05-30 주식회사 이노보테라퓨틱스 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
MX2024008076A (es) 2022-01-24 2024-07-12 Lg Chem Ltd Formulacion inyectable que contiene derivado de isoxazolina.
WO2023163470A1 (ko) * 2022-02-23 2023-08-31 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법
KR20230141971A (ko) 2022-03-24 2023-10-10 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990079267A (ko) 1998-04-03 1999-11-05 성재갑 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제
KR100373375B1 (ko) * 1998-04-03 2003-06-12 주식회사 엘지생명과학 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제
WO2001021599A1 (en) 1999-09-17 2001-03-29 Lg Chemical Ltd. Caspase inhibitor
WO2001021600A1 (en) * 1999-09-17 2001-03-29 Lg Chem Investment Ltd. Caspase inhibitor
KR100594544B1 (ko) 2003-08-27 2006-06-30 주식회사 엘지생명과학 이소옥사졸린 구조를 갖는 캐스파제 저해제
US7446127B2 (en) * 2003-08-27 2008-11-04 Sk Holdings Co, Ltd. Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders

Also Published As

Publication number Publication date
NO20074895L (no) 2007-11-26
AP2374A (en) 2012-03-07
TWI377205B (en) 2012-11-21
CN101128459B (zh) 2011-10-05
ZA200707202B (en) 2008-10-29
US8044080B2 (en) 2011-10-25
SI1851214T1 (sl) 2012-11-30
EA200701810A1 (ru) 2008-02-28
EP1851214A4 (en) 2009-10-28
CN101128459A (zh) 2008-02-20
KR20060094868A (ko) 2006-08-30
BRPI0607330A2 (pt) 2009-09-29
PL1851214T3 (pl) 2013-03-29
JP4961357B2 (ja) 2012-06-27
MA29311B1 (fr) 2008-03-03
MX2007010338A (es) 2007-10-11
AR055314A1 (es) 2007-08-15
BRPI0607330B1 (pt) 2021-08-03
KR100774999B1 (ko) 2007-11-09
PT1851214E (pt) 2012-10-18
AU2006217293B2 (en) 2012-02-02
DK1851214T3 (da) 2012-10-15
EA013005B1 (ru) 2010-02-26
CA2598347A1 (en) 2006-08-31
HK1111146A1 (en) 2008-08-01
EP1851214A1 (en) 2007-11-07
MY149181A (en) 2013-07-31
ES2394480T3 (es) 2013-02-01
PE20061076A1 (es) 2006-12-27
CA2598347C (en) 2011-08-02
TW200640918A (en) 2006-12-01
IL185226A0 (en) 2008-02-09
NO341347B1 (no) 2017-10-16
US20080262032A1 (en) 2008-10-23
EP1851214B1 (en) 2012-09-05
WO2006090997A1 (en) 2006-08-31
UA94395C2 (ru) 2011-05-10
NZ560805A (en) 2010-12-24
JP2008531551A (ja) 2008-08-14
AU2006217293A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
SG152274A1 (en) Dalbavancin compositions for treatment of bacterial infections
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
TW200624426A (en) BACE inhibitors
SG136953A1 (en) Aqueous cleaning composition and method for using same
WO2007075870A3 (en) Processes for taxane derivatives and intermediates useful therein
SG153856A1 (en) Chemical process
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
SG142306A1 (en) Methods for neuroprotection
WO2006079720A8 (fr) Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants
IL200000A (en) Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds
SG158860A1 (en) Processes for the preparation of aminoethoxybenzyl alcohols
HK1122064A1 (en) Starter kit for the production of pure and high quality microalgae
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
NO20091140L (no) Fremgangsmate for fremstilling av polyester nanokompositter
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
SG158857A1 (en) Preparation of ketone amides
SG144920A1 (en) Method and intermediates for the preparation of derivatives of n-(1- benzhydrylazetidin-3-yl)-n-phenylmethylsulphonamide
WO2007063556A3 (en) An improved and industrial process for the preparation of alfuzosin hydrochloride and its novel polymorphs
TW200732342A (en) Process for the preparation of purified crystalline CCI-779
NO20053829L (no) Fremgangsmate og intermediater for fremstilling av olanzapin.
TW200800972A (en) Process for the preparation of dioxane derivatives